Citi initiated coverage of Vertex Pharmaceuticals (VRTX) with a Buy rating and $575 price target The firm believes Vertex is positioned to remain a leader in the cystic fibrosis, or CF, space, with its current product portfolio of Trikafta, Kalydeco, Orkambi, Symdeko and the anticipated approval of the vanza triple which has a PDUFA goal date of January 2, 2025. The firm sees the vanza triple product taking a “notable portion” of the CF market with $8B sales in 2030, the analyst tells investors.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
- Vertex Pharmaceuticals price target raised to $408 from $361 at Canaccord
- Vertex Pharmaceuticals price target raised to $451 from $437 at RBC Capital
- Vertex Pharmaceuticals price target raised to $486 from $480 at Scotiabank
- Vertex Pharmaceuticals price target raised to $560 from $502 at Bernstein